Macomb, Michigan (PRWEB) April 30, 2016
A recent report published by CBC News on April 4th, 2016 questioned the use of the HyProCure sinus tarsi implant. (http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494) The news organization referred to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to correct the partial displacement of the ankle bone (talus) on the heel bone (calcaneus).
As part of the report, CBC News interviewed a patient who believed she had HyProCure inserted into her foot, and subsequently suffered from the mal-effects of the procedure. GraMedica, the owner of HyProCure, performed a detailed inquiry and determined the patient had an imitation device implanted, not HyProCure. GraMedica has tried to counteract this type of fraudulent behavior by including a special patient HyProCure identification card within each sterilized, packaged HyProCure box.
The report also cited an orthopedic surgeon who alleged there is not enough literature to support the procedure. “…[I]n the province of Ontario, as far as I know, no orthopedic surgeon has used HyProCure,” Dr. Steve Papp told the news organization. However, The positive effects of HyProCure is presented at both orthopedic and podiatric scientific conferences regularly.
HyProCure was cleared for use by the Food and Drug Administration (FDA) in 2004 and Health Canada since 2006. It is currently approved in 60 countries, and is used by leading orthopedic and podiatric surgeons. More than a dozen peer-reviewed studies have proven the safety and effectiveness of the HyProCure stent. Dozens of published reports in orthopedic and podiatric medical journals expound upon the positive role of this minimally invasive, joint-preserving procedure.
HyProCure has the greatest published success rate among sinus tarsi implants, with a removal rate of less than 6 percent. Other devices have published removal rates ranging from 40 to 100 percent, depending on design. GraMedica has partnered with the Graham International Implant Institute to provide quality-based training programs to surgeons interested in using HyProCure.
The use of sinus tarsi implants, when indicated, has increased in popularity among foot surgeons over the last few decades. EOTTS-HyProCure offers an alternative solution to patients when orthotics are not able to provide enough support, but rearfoot reconstructive surgery is too aggressive. The procedure is reversible, and the benefits far outweigh potential, minimal risks.
GraMedica is a global foot care solutions company passionate about creating innovative foot and ankle products that improve patient options and outcomes. To learn more, please visit our website at http://www.GraMedica.com. For more information on HyProCure®, please visit HyProCure.com.